Drug intelligence / Profile preview

4-Amino-2-[(3-chlorophenyl)amino]-5-(4-fluorobenzoyl)-1,3-thiazol-3-ium

Development stage: Unknown
Modality: Small Molecules

Overview

A synthetic small molecule with the chemical formula C16H12ClFN3OS and a molecular weight of approximately 348.8 g/mol. It is classified as an experimental compound and has not been approved for any medical use in the US or other regions. There are no known clinical trials or approved indications for this drug. Its mechanism of action, pharmacological properties, and therapeutic potential have not been described in publicly available sources[1][2][4]. The compound is referenced by DrugBank (DB07489) and PubChem (CID 10062702), but no further biological or clinical data are available.

Other names: 5-(4-fluorobenzoyl)-1,3-thiazol-3-ium

Beyond the preview

Go deeper on 4-Amino-2-[(3-chlorophenyl)amino]-5-(4-fluorobenzoyl)-1,3-thiazol-3-ium.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 4-Amino-2-[(3-chlorophenyl)amino]-5-(4-fluorobenzoyl)-1,3-thiazol-3-ium.

Explore the full profile